浩欧博 (688656)

1. Key Indicators

• Total Shares(W): 6347.97
• Circulating A-Shares(W): 6347.97
• Earnings Per Share(RMB): 0.4200
• Net Assets Per Share(RMB): 13.0601
• Operating Revenue(W RMB): 29217.76
• Total Profit(W RMB): 2652.64
• **Net Profit Attributable to Parent(W RMB) **: 2618.92
• Net Profit Growth Rate(%): -1.41
• Weighted Return on Equity(%): 3.1900
• Operating Cash Flow Per Share(RMB): 0.9080
• Undistributed Profit Per Share(RMB): 2.8598
• Capital Reserve Per Share(RMB): 9.0101

---

2. Main Business

The main business covers:

• Research, development, production, and sales of in vitro diagnostic reagents.

---

3. Company Basic Information

• Company Name: Jiangsu HOB Biotech Group Co., Ltd.
• Listing Date: 2021-01-13
• Industry: Pharmaceutical Manufacturing
• Address: Building C6-101, BioBay, 218 Xinghu Street, Suzhou Industrial Park, Jiangsu Province
• Website: https://www.hob-biotech.com/
• Company Profile: According to the audit report issued by Lixin Certified Public Accountants on June 30, 2017, the company's audited net assets as of February 28, 2017, were RMB 57,834,463.59. An asset appraisal institution assessed the assets, liabilities, and owner's equity of HOB Biotech Co., Ltd. as of February 28, 2017. Beijing Guorong Xinghua Asset Appraisal Co., Ltd. issued an appraisal report on April 2, 2019. On July 19, 2017, the company held its inaugural meeting and the first interim shareholders' meeting. The audited net assets of HOB Biotech Co., Ltd. as of February 28, 2017, were RMB 57,834,463.59, which were converted into 45 million shares at a ratio of 1:0.7781. The total share capital of the joint-stock company was 45 million shares, with a par value of RMB 1 per share, and the registered capital was RMB 45 million. The promoters held shares in the joint-stock company in proportion to their equity in the limited company. The excess of net assets over the registered capital, RMB 12.8345 million, was included in the capital reserve of the joint-stock company. HOB Biotech Co., Ltd. was formally transformed into Jiangsu HOB Biotech Group Co., Ltd. On August 3, 2017, Lixin Certified Public Accountants issued a capital verification report. On August 3, 2017, the company completed the foreign-invested enterprise change registration procedures with the Suzhou Industrial Park Administrative Approval Bureau. On August 11, 2017, the Jiangsu Provincial Administration for Industry and Commerce issued the Business License, officially changing HOB Biotech Co., Ltd. to a joint-stock company.

---

4. Top 10 Circulating Shareholders

Rank	Institution Name	Institution Type	Shares Held (W)	Percentage Held (%)
1	Beijing Huihuang Runkang Pharmaceutical Development Co., Ltd.	Corporate Entity	1867.09	29.41
2	Shuangrun Zhengan Information Consulting (Beijing) Co., Ltd.	Corporate Entity	1432.62	22.57
3	Hairui Xiangtian Biotechnology (Group) Co., Ltd.	Corporate Entity	763.14	12.02
4	Suzhou Wai Run Investment Management Partnership (Limited Partnership)	Corporate Entity	220.30	3.47
5	Guangzhou Jinyuan Kuntong Equity Investment Management Co., Ltd. - Guangzhou Jinhe Venture Capital Partnership (Limited Partnership)	Asset Management Plan	61.06	0.96
6	ABC-CA Healthcare Theme Stock型证券投资基金	Fund	46.24	0.73
7	Huaan Medicine & Biology Stock Initiation Securities Investment Fund Class A	Fund	36.37	0.57
8	ABC-CA Innovative Healthcare Mixed Securities Investment Fund	Fund	20.44	0.32
9	Industrial Global Healthcare Mixed Securities Investment Fund Class A	Fund	9.69	0.15
10	Huaan Anjin Flexible Allocation Mixed Initiation Securities Investment Fund Class A	Fund	1.89	0.03

---

5. Concept Sectors

• Margin Trading & Securities Lending
• Foreign Investment Background
• High Price-to-Book Ratio
• Recent Highs
• High-Price Stocks
• Control Change
• Sci-Tech Innovation 200

---

Remarks

• Data update date: 2025-09-30
• Data source: Public Market Information